# US 2006/0154287 A1 · High-content screening for drugs against cancer and age-related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154287 A1
- Document ID: US20060154287A1
- Status: Published application
- Kind: A1
- Application number: 11/331,429
- Filed: 2006-01-12
- Published: 2006-07-13
- Earliest claimed: 2005-01-13
- Assignees: Senex Biotechnology, Inc.
- Inventors: Bey-Dih Chang; Igor Roninson
- Web page: https://patentgrep.com/patent/US20060154287A1

## CPC

- G01N 33/5017: {for testing neoplastic activity}
- C12Q 1/6897: involving reporter genes operably linked to promoters
- G01N 33/5011: {for testing antineoplastic activity}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to methods for high-throughput screening for compounds that modulate cell growth or promoter activity. The invention provides the use of cell lines with properly regulated promoter-reporter expression, suitable for high-throughput screening. More particularly, the invention relates to such screening to identify compounds that affect cell growth and/or that modulate the effect of cell cycle arrest on the function of a promoter that is responsive to cell cycle inhibition.

## Claims

### Claim 1

A method for identifying a bioactive substance that has a differential effect on the growth or survival of proliferating and growth-arrested cells comprising contacting cells comprising an inducible promoter operatively associated with a gene that encodes a protein that directly or indirectly inhibits cell cycle progression with a test bioactive substance under conditions in which the inducible promoter is activated or not activated and assaying for total cell number or total cell mass, wherein the test bioactive substance is identified as a substance that has a differential effect on the growth or survival of proliferating and growth-arrested cells if the total cell number or total cell mass under conditions in which the inducible promoter is activated or not activated is different in the presence of the bioactive substance compared to the total cell number or total cell mass in the absence of the bioactive substance.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the test compound is identified as a growth inhibitory compound with specificity for proliferating cells if the total cell number or total cell mass decreases in the presence of the compound under conditions where the promoter is not activated to a greater degree than under conditions where the promoter is activated.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the test compound is identified as a compound that is toxic to growth arrested cells if the total cell number or total cell mass decreases in the presence of the compound under conditions where the inducible promoter is activated compared to the total cell number or total cell mass in the absence of the compound.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the test compound is identified as a compound that counteracts growth inhibition if the total cell number or total cell mass increases in the presence of the compound under conditions where the inducible promoter is activated compared to the total cell number or total cell mass in the absence of the compound.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the total cell number is determined by assaying the total DNA content of the cells.

### Claim 6 (depends on 5)

The method according to claim 5, wherein total DNA content of the cells is assayed by adding a detectable DNA binding agent and measuring the amount of the detectable DNA binding agent associated with DNA.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the DNA binding agent is detected by fluorometry.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the DNA binding agent is Hoechst 33342.

### Claim 9

A method for identifying a bioactive substance that modulates the effect of cell cycle inhibition on the function of a promoter that is responsive to cell cycle inhibition comprising contacting cells comprising a first inducible promoter operatively associated with a gene that encodes a protein that directly or indirectly inhibits cell cycle progression and a second promoter responsive to cell cycle inhibition and operatively associated with a gene encoding a detectable protein with test bioactive substance under conditions in which the first promoter is activated or not activated, assaying for total cell number, assaying for the detectable protein, determining the ratio of detectable protein to the total cell number, wherein the test bioactive substance is identified as a substance that modulates the effect of cell cycle arrest on transcription if the ratio of detectable protein to the total cell number under conditions in which the first promoter is activated or not activated is different in the presence of the bioactive substance compared to the ratio in the absence of the bioactive substance.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the second promoter is up-regulated under conditions of cell cycle arrest.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the second promoter is down-regulated under conditions of cell cycle arrest.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the second promoter is activated by the protein that inhibits cell cycle progression.

### Claim 13 (depends on 9)

The method according to claim 9, wherein the second promoter is down-regulated by the protein that inhibits cell cycle progression.

### Claim 14 (depends on 9)

The method according to claim 9, wherein the test compound is identified as an activator of a cyclin-dependent kinase inhibitor if the promoter responsive to cell cycle inhibition is stimulated by a cyclin-dependent kinase inhibitor and the ratio of the detectable protein to the total cell number increases in the presence of the test compound under conditions in which the first inducible promoter is not.

### Claim 15 (depends on 9)

The method according to claim 9, wherein the protein expressed from the first promoter is p21.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the test compound is identified as an inhibitor of a transcriptional effect but not of a cell cycle inhibitory effect of a cyclin-dependent kinase inhibitor if the ratio of the detectable protein to the total DNA content decreases in the presence of the compound under conditions where the promoter is activated, and if there is little or no change in the ratio of the total cell number under conditions where the first promoter is not activated to the total cell number under conditions where the first promoter is activated compared to the ratio in the absence of the test compound.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the test compound is identified as inhibitor of cell cycle inhibitory effect of a CDK inhibitor protein if the ratio of the total cell number under conditions where the first promoter is not activated to the total cell number under conditions where the first promoter is activated decreases compared to the ratio in the absence of the test compound.

### Claim 18 (depends on 9)

The method according to claim 9, wherein the total cell number is determined by assaying the total DNA content of the cells.

### Claim 19 (depends on 18)

The method according to claim 18, wherein total DNA content of the cells is assayed by adding a detectable DNA binding agent and measuring the amount of the detectable DNA binding agent associated with DNA.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the DNA binding agent is detected by fluorometry.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the DNA binding agent is Hoechst 33342.

### Claim 22 (depends on 9)

The method according to claim 9, wherein the detectable protein is a fluorescent protein.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the fluorescent protein is detected by fluorometry.

### Claim 24 (depends on 28)

The method according to claim 28, wherein the fluorescent protein is green fluorescent protein.

### Claim 25

A method for identifying a bioactive substance that has an effect either on cell growth or a promoter responsive to cell cycle inhibition comprising contacting cells comprising a first inducible promoter operatively associated with a gene that encodes a protein that directly or indirectly inhibits cell cycle progression and a second promoter responsive to cell cycle inhibition and operatively associated with a gene encoding a detectable protein with test bioactive substance under conditions in which the first promoter is activated or not activated, assaying for total cell number, assaying for the detectable protein, determining the ratio of detectable protein to the total cell number, wherein the test bioactive substance is identified as a substance that has an effect on cell growth if the total cell number under conditions in which the first promoter is activated or not activated is different in the presence of the bioactive substance than in the absence of the bioactive substance, and as a substance that has an effect on a promoter responsive to cell cycle inhibition if the ratio of detectable protein to the total cell number under conditions in which the first promoter is activated or not activated is different in the presence of the bioactive substance compared to the ratio in the absence of the bioactive substance.
